Filing Flows › Regenxbio (RGNX) › Q1 2025
Regenxbio (RGNX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
Regenxbio (RGNX) reported revenue of $89.0M for the first quarter 2025 (Q1 2025), +470% from a year earlier and +320% from the quarter before. Operating margin was 13.6%, net earnings $6.1M (6.8% of revenue).
Regenxbio, Q1 2025: revenue $89.0M (+470% year over year), operating margin 13.6%, net earnings $6.1M, operating cash flow $33.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $89.0M | +320% | +470% |
| Operating profit | $12.1M | — | — |
| Net earnings | $6.1M | — | — |
| Operating cash flow | $33.6M | — | — |
| Free cash flow | $32.6M | — | — |
What changed
Revenue was $89.0M in Q1 2025, up 470% year over year and up 320% from the previous quarter. Nippon Shinyaku Licenses was the largest line at 79% of revenue. Zolgensma Royalties added $1.8M year over year (up 12%), 2% of the total change. Other Service Revenue declined 32%.
Operating profit was $12.1M, a 13.6% margin (up 422.4 points year over year). Total costs fell 3% while revenue rose 470%. The fastest-growing cost line was Other operating costs (+67%). Net earnings were $6.1M. The effective tax rate was 0.0%.
Operating cash flow was $33.6M, 553% of net earnings. Non-cash charges added back $4.0M of depreciation and amortization and $8.5M of share-based compensation. Working capital and other items added $15.1M. Capital expenditures of $1.0M left free cash flow of $32.6M.
Questions
What was Regenxbio's revenue in the first quarter 2025?
Regenxbio (RGNX) reported revenue of $89.0M for the first quarter 2025 (Q1 2025), +470% from a year earlier and +320% from the quarter before.
Was Regenxbio profitable in the first quarter 2025?
Operating profit was $12.1M (13.6% of revenue) and net earnings $6.1M.
Source: Regenxbio 10-Q on SEC EDGAR.